Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 9/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.68 |
| ▸ | FLT3 | P36888 | 7/20 | 0.68 |
| ▸ | FLT4 | P35916 | 4/20 | 0.68 |
| ▸ | MET | P08581 | 7/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161704 | 0.90 | PDGFRB (0.65) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL4156316 | 0.88 | CSF1R (0.73) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL4514191 | 0.81 | MET (0.50) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL4149487 | 0.80 | PDGFRB (0.85) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL4300136 | 0.79 | CSF1R (0.70) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL4156186 | 0.78 | CSF1R (0.60) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL4143903 | 0.77 | PDGFRB (0.70) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL4521831 | 0.75 | PDGFRB (0.66) | CSF1RPDGFRBFLT3FLT4KDR | |
| SCHEMBL4152898 | 0.75 | CSF1R (0.67) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL2176647 | 0.74 | PDGFRB (0.83) | CSF1RPDGFRBFLT3FLT4MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036485-A1 | Quinoline derivatives | JUNG FREDERIC HENRI | 2009-02-05 | — | — | US | disclosed |
| EP-1802603-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040522-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036485-A1 | Quinoline derivatives | AQP3, PGF, AQP1 | CSF1R 557/4885PDGFRB 537/4885FLT3 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.